Purpose The molecular specificity of monoclonal antibodies (mAbs) directed against tumor antigens has proven effective for targeted therapy of human cancers, as shown by a growing list of successful antibody-based drug products. We describe a novel, nonlinear compartmental model using PET-derived data to determine the "best-fit" parameters and model-derived quantities for optimizing biodistribution of intravenously injected 124 I-labeled antitumor antibodies.
Introduction
Our laboratory has a longstanding interest in antigenselective tumor targeting with radiolabeled antibodies for radioimmunotherapy (RIT) of solid tumors and has, for example, performed a study of the tumor and normaltissue uptake and kinetics of an 124 I-labeled humanized anti-A33 mAb, huA33, in colorectal cancer patients, using PET with tissue sampling during surgery [1, 2] . We determ i n e d t h a t : P E T i m a g i n g c a n a c c u r a t e l y a n d Douglas Wong, and Lloyd J. Old were deceased.
noninvasively quantitate the time-dependent antibody concentrations in vivo; the "equilibrium" uptake of radiolabeled huA33 in A33-expressing normal and tumor tissues is driven primarily by the antigen concentration; and such uptake is saturable. It should therefore be possible to develop a PET-based kinetic model which would provide key parameters regarding in vivo uptake in tumor and normal tissue. Importantly, because of the saturability of the antibody-antigen interaction, nonlinear analysis would be required for patient-specific optimization of therapeutic antibody-targeting strategies.
We report here the development and initial validation of a nonlinear compartmental model of the in vivo biodistribution and kinetics of huA33 based on PET imaging of 124 I-huA33. This compartmental modeling approach can be used to predict, on a patient-specific basis, the optimal therapeutic dose of radiolabeled huA33 as well as the antigen occupancy, persistence times in normal and malignant tissues, and the colorectal cancer-tonormal colon therapeutic index. In addition, nonlinear compartmental modeling may be readily applied to the development of strategies such as multistep targeting (MST) designed to further improve the therapeutic indices of RIT.
The choice of A33 antigen as the in vivo target of this initial study was based on the unique features of the antigen-antibody interaction. The expression of the A33 transmembrane glycoprotein is restricted to normal human bowel and colon cancer (95 %), gastric cancer (95 %), and pancreatic cancer (50 %) [3, 4] . Upon binding of anti-A33 mAb, the resulting noninternalized antibody-antigen complex persists on the cell surface for several weeks [5] . Such a lengthy membrane persistence time is quite uncommon among antibody-antigen complexes, and makes anti-A33 mAb particularly attractive for use in RIT. In contrast, turnover of A33-expressing cells in normal bowel is rapid, occurring every 5 -6 days by exfoliation of mucosal cells into the bowel lumen.
Clinical studies with murine anti-A33 mAb have demonstrated its safety, tumor-targeting ability, and specificity [6] [7] [8] , even though development of human anti-mouse antibody (HAMA) was common and resulted in accelerated clearance of subsequent administrations of the mAb [8] . Initial trials with huA33 alone or combined with chemotherapy have shown favorable tolerability, some evidence of therapeutic response [9, 10] , and less immunogenicity than murine anti-A33 mAb [10] [11] [12] .
This combination of long persistence of antigen on the surface of tumor cells, a significant "off-target" antigen pool in the colon, the high percent uptake in tumor, and demonstrated safety and tolerability of multiple administrations in humans make the A33 antigen-antibody system a suitable model for initial studies with our PET-based nonlinear kinetic modeling approach.
Materials and methods

A33 antibody and radiolabeling
HuA33 is a fully humanized IgG1 mAb derived from murine A33 antibody by complementarity determinant region (CDR) grafting [13] and was produced and characterized as previously described [14, 15] I was incubated with huA33 (7 mg, 0.1 M phosphate buffer pH 7.4) in an iodogen tube. After a 20-min incubation, the mixture was purified through an anion exchange column followed by terminal sterilization through a 0.22-μm filter. The activity of the final product was assayed in a dose calibrator and cold antibody was added to yield a specific activity of between 0.1 and 1 mCi/mg. All products passed pyrogen and sterility testing. The median radiochemical yield was 95 %, radiochemical purity 99.2 %, and immunoreactivity 89 %, as determined by a cell-binding assay using SW1222 cells [16] . The use of a long-lived positron emitter, 124 I, and the ability to thereby extend kinetic measurements to about 1 week after injection was an important practical feature of the current study in terms of the fitting of our model.
Patient eligibility and protocol design
Patients were enrolled in an open-label prospective protocol approved by the MSKCC Institutional Review Board to evaluate the safety, pharmacokinetics, biodistribution, and tumortargeting properties of intravenously administered 124 IhuA33. Subjects were at least 18 years of age and had histologically confirmed primary or metastatic colorectal and were candidates for clinically indicated laparotomy for tumor resection or were nonsurgical candidates with liver metastasis larger than 2.5 cm. All subjects provided written and oral informed consent. A subset of 11 (out of a total of 19) subjects having multiple PET or PET/CT scans were included in the current analysis; the 8 124 I-huA33 patients not included in this analysis had only one or two PET/CT scans performed, and thus did not have sufficient time-activity data for kinetic modeling.
Subjects received a single intravenous administration of standard to convert net count rates to activity, and the activity concentration (percent of the injected dose per gram, %ID/g) decay-corrected to the time of injection was determined.
Imaging and derivation of tissue activities
Patients were imaged on a General Electric Advance PET scanner or Discovery LS or DSTE PET-CT scanner in 2D mode with attenuation, scatter, and other standard corrections applied. Images were acquired for 6 min per bed position and included whole-torso imaging from the neck to the proximal thighs or from the mid-chest to the pelvis. For the cohort analyzed in the current study, the initial images were acquired 3 h following administration of 124 I-A33 and the final images at a median of 8.9 days after tracer administration.
Images were read on a dedicated PET analysis workstation (AW Suite; GE Healthcare, Barrington, IL) by an experienced nuclear medicine physician (J.A.C.) who was aware of the patient's history and diagnostic CT report. Localization in tumor was defined as focal accumulation greater than adjacent background in areas where physiologic activity is not expected. Bowel activity foci were considered positive for tumor when there was an accumulation greater than that in adjacent bowel. Regions of interest were manually placed over structures of interest and mean standardized uptake values (SUV) were determined for blood pool, tumor, and small and large bowel as (activity in region in nanocuries per milliliter)/ (injected activity in nanocuries/body mass in grams). In order to derive the mean tissue activity concentration in %ID/g, the SUV was divided by the body weight (in grams) and multiplied by 100.
Tumor masses were estimated by CT (assuming a mass density of 1 g/ml) or by weighing of surgically excised lesions. By multiplying the tumor masses thus determined by the PET-derived activity concentrations (in %ID/g), the total activities (in %ID) in tumor were determined at each of up to four imaging time-points; an illustrative series of 124 I-huA33 PET images is shown in Fig. 1 . A33-expressing cells in normal bowel are restricted to the intestinal mucosa, including the self-renewing intestinal crypt cells, and thus comprise only a small portion by mass of the bowel wall: of the 1,000-g total mass of the bowel wall in the 70-kg "Reference Man" [17] , only 7 g is intestinal mucosa according to the small-scale anatomic model for bowel of Fisher et al. [18] . For all patients in the current analysis, therefore, the activity in the A33-expressing mucosa was calculated using 7 g as the mass of this tissue.
Blood sampling and counting
Blood samples were drawn from all subjects from the antecubital vein contralateral to the vein used for infusion at approximately 5, 15, 60 and 120 min after antibody administration and on the last day of imaging or the day of surgery (5 -9 days after antibody infusion); in some subjects, an additional blood sample was drawn at 24 -72 h after administration with concomitant imaging. All samples were centrifuged and plasma was aliquoted, weighed, and counted as described above for the tissue samples. The plasma activity concentrations in %ID/g were multiplied by the total plasma volume, calculated based on the patient's height and weight, to yield the total plasma activity in %ID.
Compartmental modeling
The plasma, normal bowel, and tumor time-activity data for each patient were fit to the nonlinear compartmental model, that is, the three differential equations shown in Fig. 2 , using the SAAM II (Simulation, Analysis, and Modeling) program [19] [20] [21] . The measured plasma time-activity data provide the direct input function for tumor and bowel, eliminating the need to explicitly account for the anti-A33 mAb in the rest of the body (i.e. in tissues other than plasma, bowel, and tumor). For fitting, the starting values of the association rate constant (k a ), 1 the total A33 concentration in normal bowel Fig. 1 Coronal PET maximum-intensity projection images of a patient with colorectal cancer metastatic to the liver at 2 and 7 days after injection of 124 I-huA33 mAb. The 2-day image shows two high-uptake foci in the liver (single arrow) and splenic flexture (double arrow) corresponding to known metastic lesions and some uptake in the bowel. At 7 days, there is persistent uptake in the liver metastases and prominent uptake in normal bowel (triple arrow). For this patient, the model-derived A33 concentrations in tumor and normal bowel were 500 and 20 nM, respectively, and the maximum A33 occupancies 10 % and 1 %, respectively. These occupancy values are at the low end of the range for our patient cohort (see Table 1 second terms (i.e. the differences) in these two formulas make k(2,1) and k(3,1) time-varying parameters and thus introduce nonlinearities into the model.
Results
For the current analysis, and as described by Carrasquillo et al. [2] , serial blood sampling, plasma counting, and whole-body PET imaging were performed up to about 1 week following intravenous injection of each of 11 colorectal cancer patients with 10 mg of the humanized anti-A33 mAb (huA33) labeled with 10 mCi of 124 I. The resulting kinetic data for each patient were fit to a compartmental model (Fig. 2) using the SAAM II program [19] [20] [21] . As illustrated in Fig. 3 , showing the modelpredicted and measured time-activity data for one patient in the current cohort, our nonlinear compartmental analysis yielded excellent goodness of fit of the model to the measured time-activity data; the model's goodness of fit to this patient's kinetic data is typical of that for all 11 patients analyzed. For 10 of the 11 patients, the Z-statistic indicated that the model fits were statistically acceptable at a 5 % significance level. The validity of our proposed model is further corroborated by the agreement between the antigen concentration in tumor derived from the model and from in vitro binding studies of cell membrane fractions obtained from resected tumor specimens [1] . Among the three patients in our cohort for whom the latter analysis was performed, the model-derived and average binding study-derived antigen concentrations were 30 and 45 nM, 45 and 54 nM, and 15 and 6.1 nM. The "best-fit" model parameters for our 11-patient cohort are summarized in Table 1 .
Discussion
In contrast to typical, "nonsaturable" kinetics, the model presented in Fig. 2 is nonlinear. As a result of the saturable binding of the anti-A33 mAb to the A33 antigenic sites, characteristic of antibody-antigen interactions generally, the exchange rate for the binding of the mAb to antigen progressively decreases as increasing numbers of antigenic sites are occupied by the antibody. The practical implications of the nonlinearity of antibody-antigen interactions for immune targeting and the ability to predictively model these interactions on an individual patient basis are significant. The concentration of A33 in targeted tumors and the total mass of the A33-expressing tumor, and therefore the total number of A33 binding sites, may vary widely among patients, and the anti-A33 mAb-to-A33 exchange rate in vivo and thus the tumor concentration and tumor-to-normal tissue ratios of the antibody will vary as well. The latter parameters will also vary as the dose of antibody (in moles) is varied. As a result, there is no single optimum antibody dose which is translatable from patient to patient, even adjusted for body mass, body surface area etc. Rather, a more rational approach to optimizing RIT requires administration of a pretherapy tracer of the mAb to the patient, imaging-based measurement of its time-activity data in blood, tumor, and antigen-expressing normal tissue(s), fitting of these data to the nonlinear model, and model-based determination of the optimum antibody dose (in moles) for that patient; the patient-specific optimum antibody dose for RIT is that which yields the maximum tumor-to-normal tissue area under the curve (AUC) concentration ratios, and thus the maximum tumor-to-normal tissue absorbed-dose ratios. For example, computer simulations were performed using the "best-fit" model parameters (see Fig. 2 ) for the patient whose images are shown in Fig. 1 . The simulation results indicated that tumor targeting of huA33 mAb, expressed as the tumor-tonormal colon and tumor-to-plasma AUC concentration ratios, could be nearly doubled by increasing the administered dose of antibody from 10 to 50 mg. The simulations also show that there would have been little additional increase in these ratios with a further increase in the antibody dose (data not shown). Thus, once a "best-fit" model for the patient-specific tracer kinetics has been deduced, the optimum mAb dose can be determined by model simulation of tumor, blood, and antigen-expressing normal tissue kinetics (including AUCs) for different, systematically varied mAb doses.
In a recent study from our laboratory further demonstrating the utility of nonlinear modeling in characterizing immune reagents in vivo [22] , the binding affinities and internalization kinetics of A long-term objective is to exploit the unique properties of A33 as an antigenic target and extend the foregoing paradigm to individualized RIT, including MST-based RIT, of colorectal cancer and solid tumors generally. (As the data in Table 1 indicate, directly labeled anti-A33 mAb typically yields I-A33 into a colorectal cancer patient. The points represent the measured data and the curves the "best-fit" modelderived data obtained using the model in Fig. 2 . For this patient, the bestfit model-derived tumor and normal colon A33 concentrations were 2.0 and 4.5 nM, respectively, and the antibody-antigen association rate constant 6.5 × 10 −9 /M/h tumor-to-normal tissue ratios of the order of only several-toone or less, which may be inadequate for safe and effective RIT, at least for relatively large tumor burdens. Conceivably, however, higher tumor-to-normal tissue ratios may be achieved with smaller residual tumors following conventional front-line therapy.) The physiology of A33-expressing normal cells makes A33 a uniquely appealing target for MST-based RIT of colon cancer [23, 24] . By temporally dissociating delivery of the A33 mAb construct (e.g. streptavidinated mAb or a bifunctional antibody construct as mentioned below) and the therapeutic radionuclide, potential therapy-limiting irradiation of the intestinal crypt cells is avoided because the A33 mAbbinding crypt cells are turned over and replaced prior to administration of the radionuclide carrier (e.g. metal chelatorbiotin) designed to bind to the A33-mAb complex. Our planned MST strategy will be pursued in collaboration with Dane Wittrup and colleagues of the Massachusetts Institute of Technology, utilizing Dr. Wittrup's bispecific tetravalent anti-A33/-[metal-DOTA] antibody construct (nALDO) which reacts with A33 and with radiometallabeled DOTA-Bn (DOTA-Bn: ((2-(4-aminobenzyl)-1,4,7, 10-tetraazacyclododecane-1,4,7,10-tetrayl) tetraacetic acid) [25] . Importantly, our current proof-of-principle results demonstrate that acquisition and accurate nonlinear modeling of kinetic data of A33 and tumor-targeted immune constructs generally are clinically practical. Further, the model utilized in the current analysis is adaptable to MST and thus can be used to predict not only the patient-specific optimum dose (in moles) of the construct but also the optimum times of administration of the clearing agent and of the radionuclide carrier. The current results thus point the way to this practically achievable, important advance in individualized cancer therapy.
Finally, we believe that the clinical implications of this work are potentially far-reaching. Over the last decade, mAbs as a class of drugs have achieved critical importance in oncology both clinically and commercially. It is projected, for example, that by 2016 four of the five top oncology products in the world will be antibody-based pharmaceuticals, i.e. rituximab (Rituxan™), trastuzumab (Herceptin™), bevacizumab (Avastin™) and cetuximab (Erbitux™), will reach $75 -80 billion in global sales from $48 billion in 2008 [26] . Nonetheless, despite the clinical and commercial importance of antibodies to oncology, factors which impact their in vivo biodistribution and thus their biologic effectiveness remain poorly understood. For this reason, optimized dose and dosing scheduling continue to be determined empirically, by laborious, time-consuming and costly dose-escalation studies. Although we are primarily interested in RIT methodologies, our nonlinear kinetic modeling approach is general and applicable to any antibody-antigen system for which antigen occupancy is the mechanism for the antitumor effect or normal organ toxicity. The work presented provides the basis for a practical, scientifically rational, and cost-effective approach to the clinical optimization of such therapeutics.
